A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Pimodivir (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Therapeutic Use
  • Acronyms Topaz
  • Sponsors Janssen Pharmaceuticals; Vertex Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2017 Primary endpoint (Area under the curve (AUC) of the log10 Nasal Viral Load on Day 8) has been met, according to a Janssen Pharmaceuticals media release.
    • 14 Jun 2017 According to a Janssen Pharmaceuticals media release, resultes were presented at the 5th International Society for Influenza and Respiratory Diseases Antiviral Group (ISIRV-AVG) Conference.
    • 14 Jun 2017 Results published in a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top